Lixte Biotechnology has been granted a patent for a method involving the in vivo delivery of endothall to cancer cells in cancer patients. The method includes administering a specific compound to the patient. GlobalData’s report on Lixte Biotechnology gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

According to GlobalData’s company profile on Lixte Biotechnology, Cancer treatment biomarkers was a key innovation area identified from patents. Lixte Biotechnology's grant share as of January 2024 was 36%. Grant share is based on the ratio of number of grants to total number of patents.

In vivo delivery of endothall to cancer cells

Source: United States Patent and Trademark Office (USPTO). Credit: Lixte Biotechnology Holdings Inc

A recently granted patent (Publication Number: US11866444B2) discloses a method for delivering endothall to cancer cells in vivo in individuals with cancer. The method involves administering a compound with a specific structure to the subject. The patent claims cover the delivery of endothall specifically to cancer cells, with a focus on brain cancer, including various types such as glioblastoma multiforme, medulloblastoma, and others.

Furthermore, the method outlined in the patent also includes the administration of an anti-cancer agent in conjunction with the compound to enhance the treatment efficacy. The specific structures of the compound mentioned in the claims indicate the precise chemical composition required for effective delivery to cancer cells, particularly in the context of brain cancer. This patent highlights a novel approach to targeting cancer cells with endothall, potentially offering new treatment options for individuals with various types of cancer, especially those affecting the brain.

To know more about GlobalData’s detailed insights on Lixte Biotechnology, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies